Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06001762
Title TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Stamford Hospital Stamford Connecticut 06904 United States Details
Eastern Maine Medical Center (Northern Light) Brewer Maine 04412 United States Details
New England Cancer Specialists Scarborough Maine 04074 United States Details
Boston Medical Center Boston Massachusetts 02118 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
Dana-Farber Cancer Institute at Steward St. Elizabeth's Brighton Massachusetts 02135 United States Details
Dana-Farber Cancer Institute at Foxborough Foxborough Massachusetts 02035 United States Details
Dana-Farber Cancer Institute at Merrimack Valley Methuen Massachusetts 01844 United States Details
Dana-Farber Cancer Institute at Milford Milford Massachusetts 01757 United States Details
Dana-Farber Cancer Institute at South Shore South Weymouth Massachusetts 02190 United States Details
Dana-Farber Cancer Insitute at Londonderry Hospital Londonderry New Hampshire 03053 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field